Mike Russell
Mike Russell
Verified email at
Cited by
Cited by
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in NeuroblastomaCDK4/6 Inhibition in Neuroblastoma
JA Rader, MR Russell, LS Hart, MS Nakazawa, LT Belcastro, D Martinez, ...
Clinical cancer research 19 (22), 6173-6182, 2013
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
KA Cole, J Huggins, M Laquaglia, CE Hulderman, MR Russell, K Bosse, ...
Proceedings of the National Academy of Sciences 108 (8), 3336-3341, 2011
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility LocusCASC15 Is a Neuroblastoma Suppressor Gene
MR Russell, A Penikis, DA Oldridge, JR Alvarez-Dominguez, L McDaniel, ...
Cancer research 75 (15), 3155-3166, 2015
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in NeuroblastomaDual Inhibition of Chk1/Wee1 in Neuroblastoma
MR Russell, K Levin, JA Rader, L Belcastro, Y Li, D Martinez, B Pawel, ...
Cancer research 73 (2), 776-784, 2013
Rare Variants in TP53 and Susceptibility to Neuroblastoma
SJ Diskin, M Capasso, M Diamond, DA Oldridge, K Conkrite, KR Bosse, ...
Journal of the National Cancer Institute 106 (4), dju047, 2014
Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features
Q Liu, MR Russell, K Shahriari, DL Jernigan, MI Lioni, FU Garcia, ...
Cancer research 73 (11), 3297-3305, 2013
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaMEK1/2 and CDK4/6 Inhibitors Synergize against Neuroblastoma
LS Hart, JA Rader, P Raman, V Batra, MR Russell, M Tsang, M Gagliardi, ...
Clinical Cancer Research 23 (7), 1785-1796, 2017
Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor
NG Dolloff, MR Russell, N Loizos, A Fatatis
Cancer research 67 (2), 555-562, 2007
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal MetastasisPDGFRα Inhibition …
MR Russell, Q Liu, A Fatatis
Clinical Cancer Research 16 (20), 5002-5010, 2010
The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma
M Capasso, LD McDaniel, F Cimmino, A Cirino, D Formicola, MR Russell, ...
Journal of Cellular and Molecular Medicine 21 (12), 3224-3230, 2017
The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells
MR Russell, WL Jamieson, NG Dolloff, A Fatatis
Oncogene 28 (3), 412-421, 2009
The α-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand-and dimerization-independent mechanisms
MR Russell, Q Liu, H Lei, A Kazlauskas, A Fatatis
Cancer research 70 (10), 4195-4203, 2010
TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
WR Oliver, SJL Snaith, MR Russell, CS Plunket, KD Bodkin, NL Lewis, ...
Proc. Natl. Acad. Sci. USA 98, 5306-11, 0
Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma
MR Russell, KA Cole, JM Maris
Cancer Research 71 (8_Supplement), 4758-4758, 2011
CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas.
JA Rader, L Hart, M Russell, M Nakazawa, L Belcastro, D Martinez, ...
Cancer Research 73 (8_Supplement), 2744-2744, 2013
The long intergenic noncoding RNA LINC00340 is a neuroblastoma susceptibility gene
MR Russell, A Penikis, D Oldridge, M Diamond, S Diskin, J Maris, K Cole
Cancer Research 74 (19_Supplement), 5237-5237, 2014
Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma
M Russell, K Levin, JA Rader, C Toniatti, JM Maris, KA Cole
Cancer Research 72 (8_Supplement), 1436-1436, 2012
Endolyn contains lysosomal and apical targeting information in different domains of the protein
G Ihrke, MRG Russell, JP Luzio
Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models
S Basu, M Russell, K Sproesser, B Mattson, CL Lowenstein, ...
Cancer Research 82 (12_Supplement), LB087-LB087, 2022
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.
MJ Morris, AO Sartor, JYC Wong, SI Max, H Xie, A Yu, CR Divgi, ...
Journal of Clinical Oncology 40 (16_suppl), TPS5104-TPS5104, 2022
The system can't perform the operation now. Try again later.
Articles 1–20